Trial · NCT02663518
Participant flow126
How many started, completed or left each group, period by period.
1 to 20 of 126
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg | 3 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg | 3 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg | 7 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg | 5 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) Monotherapy for Part 2 | 0 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621)+ Nivolumab Combination | 0 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) + Rituximab Combination | 0 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) Monotherapy for Part 3 | 0 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg | 0 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg | 0 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg | 0 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg | 0 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg | 0 | |
| Part 1: Phase 1a Escalation | STARTED | Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg | 0 | |
| Part 1: Phase 1a Escalation | COMPLETED | Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg | 0 | |
| Part 1: Phase 1a Escalation | COMPLETED | Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg | 0 | |
| Part 1: Phase 1a Escalation | COMPLETED | Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg | 0 | |
| Part 1: Phase 1a Escalation | COMPLETED | Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg | 1 | |
| Part 1: Phase 1a Escalation | COMPLETED | Ontorpacept (PF-07901800/TTI-621) Monotherapy for Part 2 | 0 | |
| Part 1: Phase 1a Escalation | COMPLETED | Ontorpacept (PF-07901800/TTI-621)+ Nivolumab Combination | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02663518/flow